I was delighted to attend the launch of a $1 billion Antimicrobial Resistance (AMR) Action Fund, which aims to support vital research which hopes to bring two to four new antibiotics to market by 2030. The fund will be available to UK small and medium sized companies seeking to develop new antibiotics, those in this field will be able to apply this autumn. Find out more about the fund here.
UK PharmaScan is a database of information on new medicines, indications and formulations in the pharmaceutical
pipeline. It is the primary source of information used by all of the UK’s national horizon scanning organisations and
NHS England to enable early engagement in planning and preparing the NHS for the introduction of new medicines
and to support faster NHS adoption.
Steve Bates OBE, Chief Executive of the BIA said: “Antimicrobial resistance (AMR) is one of the key global challenges of our times. Despite being a global health (and BIA) policy focus for years, no market solution has yet delivered the incentives needed to make novel antibiotic development an attractive investment prospect.
The BIA is a supporter of the the award winning charity In2scienceUK. This year In2scienceUK has launched an ambitious Covid-19 response allowing young people across the country to gain essential skills, role models and knowledge on STEM Skills and careers. In this blog, their Development Officer Luke McKelvey tells us about the programme and how BIA members can get involved.
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization (CRO) was named Champion in multiple categories of the 2020 CRO Leadership Awards, and was the only CRO named as Champion in the Quality category.
Mogrify Ltd (Mogrify®), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board (SAB).
It was great to see NHS England agree a deal with BIA member Vertex last week, to enable their new cystic fibrosis drug combination Kaftrio available to NHS patients. This is brilliant news for the cystic fibrosis community with nine in 10 patients set to benefit from this life-transforming medicine.
The Oxford Science Park (TOSP), one of the UK's leading parks for science and technology companies, is pleased to announce that its newest facility, the 30,000 sq ft Bellhouse Building, has reached practical completion.